PD‐1/PD‐L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First‐Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study
ABSTRACT This multicenter study aimed to investigate the efficacy and safety of PD‐1/PD‐L1 inhibitors plus chemotherapy (ICI‐Chemo group) versus chemotherapy alone (Chemo group) for patients with cancer of unknown primary (CUP) in the first‐line setting. We included patients with unfavorable CUP acr...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.70124 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849393293836681216 |
|---|---|
| author | Riqing Huang Haifeng Li Shuo Li Ditian Shu Rishang Chen Zhousan Zheng Tinghua Gao Meiting Chen Anqi Hu Yunjie Huang Qiufan Zheng Xin An Cong Xue Yuchen Cai Yanxia Shi |
| author_facet | Riqing Huang Haifeng Li Shuo Li Ditian Shu Rishang Chen Zhousan Zheng Tinghua Gao Meiting Chen Anqi Hu Yunjie Huang Qiufan Zheng Xin An Cong Xue Yuchen Cai Yanxia Shi |
| author_sort | Riqing Huang |
| collection | DOAJ |
| description | ABSTRACT This multicenter study aimed to investigate the efficacy and safety of PD‐1/PD‐L1 inhibitors plus chemotherapy (ICI‐Chemo group) versus chemotherapy alone (Chemo group) for patients with cancer of unknown primary (CUP) in the first‐line setting. We included patients with unfavorable CUP across four medical centers in China. Between January 2014 and December 2023, 117 patients were enrolled: 46 patients in the ICI‐Chemo group and 71 patients in the Chemo group. After a median follow‐up of 28.1 months, the ICI‐Chemo group exhibited a significant improvement over the Chemo group in median PFS (9.10 months vs. 6.37 months; hazard ratio [HR] 0.46; 95% CI: 0.30–0.71; p < 0.001) and OS (35.67 months vs. 10.2 months; HR 0.37; 95% CI: 0.22–0.64; p < 0.001). Similarly, among patients who received TP (taxane plus platinum)‐based chemotherapies, OS and PFS benefits were observed in the ICI‐Chemo group. The objective response rate was higher in the ICI‐Chemo group than in the Chemo group (54.35% vs. 22.53%, p < 0.001). Grade 3 or higher drug‐related adverse events occurred in 11 patients (23.91%) in the ICI‐Chemo group and 28 patients (39.44%) in the Chemo group. Thus, PD‐1/PD‐L1 inhibitors plus chemotherapy could be the preferred first‐line treatment for patients with unfavorable CUP, providing improved efficacy and manageable toxicity. |
| format | Article |
| id | doaj-art-7fe5b5a62a4f4a47a7fac6328772d0c8 |
| institution | Kabale University |
| issn | 2688-2663 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | MedComm |
| spelling | doaj-art-7fe5b5a62a4f4a47a7fac6328772d0c82025-08-20T03:40:28ZengWileyMedComm2688-26632025-03-0163n/an/a10.1002/mco2.70124PD‐1/PD‐L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First‐Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort StudyRiqing Huang0Haifeng Li1Shuo Li2Ditian Shu3Rishang Chen4Zhousan Zheng5Tinghua Gao6Meiting Chen7Anqi Hu8Yunjie Huang9Qiufan Zheng10Xin An11Cong Xue12Yuchen Cai13Yanxia Shi14State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou P. R. ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou P. R. ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou P. R. ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou P. R. ChinaMedical Oncology Department III Central Hospital of Guangdong Nongken Zhanjiang P. R. ChinaDepartment of Oncology The First Affiliated Hospital of Sun Yat‐sen University Guangzhou P. R. ChinaDepartment of Oncology The First People's Hospital of Zhaoqing City Zhaoqing P. R. ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou P. R. ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou P. R. ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou P. R. ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou P. R. ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou P. R. ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou P. R. ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou P. R. ChinaState Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou P. R. ChinaABSTRACT This multicenter study aimed to investigate the efficacy and safety of PD‐1/PD‐L1 inhibitors plus chemotherapy (ICI‐Chemo group) versus chemotherapy alone (Chemo group) for patients with cancer of unknown primary (CUP) in the first‐line setting. We included patients with unfavorable CUP across four medical centers in China. Between January 2014 and December 2023, 117 patients were enrolled: 46 patients in the ICI‐Chemo group and 71 patients in the Chemo group. After a median follow‐up of 28.1 months, the ICI‐Chemo group exhibited a significant improvement over the Chemo group in median PFS (9.10 months vs. 6.37 months; hazard ratio [HR] 0.46; 95% CI: 0.30–0.71; p < 0.001) and OS (35.67 months vs. 10.2 months; HR 0.37; 95% CI: 0.22–0.64; p < 0.001). Similarly, among patients who received TP (taxane plus platinum)‐based chemotherapies, OS and PFS benefits were observed in the ICI‐Chemo group. The objective response rate was higher in the ICI‐Chemo group than in the Chemo group (54.35% vs. 22.53%, p < 0.001). Grade 3 or higher drug‐related adverse events occurred in 11 patients (23.91%) in the ICI‐Chemo group and 28 patients (39.44%) in the Chemo group. Thus, PD‐1/PD‐L1 inhibitors plus chemotherapy could be the preferred first‐line treatment for patients with unfavorable CUP, providing improved efficacy and manageable toxicity.https://doi.org/10.1002/mco2.70124cancer of unknown primarychemotherapyfirst‐line therapyoverall survivalPD‐1/PD‐L1 inhibitors |
| spellingShingle | Riqing Huang Haifeng Li Shuo Li Ditian Shu Rishang Chen Zhousan Zheng Tinghua Gao Meiting Chen Anqi Hu Yunjie Huang Qiufan Zheng Xin An Cong Xue Yuchen Cai Yanxia Shi PD‐1/PD‐L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First‐Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study MedComm cancer of unknown primary chemotherapy first‐line therapy overall survival PD‐1/PD‐L1 inhibitors |
| title | PD‐1/PD‐L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First‐Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study |
| title_full | PD‐1/PD‐L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First‐Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study |
| title_fullStr | PD‐1/PD‐L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First‐Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study |
| title_full_unstemmed | PD‐1/PD‐L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First‐Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study |
| title_short | PD‐1/PD‐L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First‐Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study |
| title_sort | pd 1 pd l1 inhibitors plus chemotherapy versus chemotherapy alone as first line therapy for patients with unfavorable cancer of unknown primary a multicenter retrospective cohort study |
| topic | cancer of unknown primary chemotherapy first‐line therapy overall survival PD‐1/PD‐L1 inhibitors |
| url | https://doi.org/10.1002/mco2.70124 |
| work_keys_str_mv | AT riqinghuang pd1pdl1inhibitorspluschemotherapyversuschemotherapyaloneasfirstlinetherapyforpatientswithunfavorablecancerofunknownprimaryamulticenterretrospectivecohortstudy AT haifengli pd1pdl1inhibitorspluschemotherapyversuschemotherapyaloneasfirstlinetherapyforpatientswithunfavorablecancerofunknownprimaryamulticenterretrospectivecohortstudy AT shuoli pd1pdl1inhibitorspluschemotherapyversuschemotherapyaloneasfirstlinetherapyforpatientswithunfavorablecancerofunknownprimaryamulticenterretrospectivecohortstudy AT ditianshu pd1pdl1inhibitorspluschemotherapyversuschemotherapyaloneasfirstlinetherapyforpatientswithunfavorablecancerofunknownprimaryamulticenterretrospectivecohortstudy AT rishangchen pd1pdl1inhibitorspluschemotherapyversuschemotherapyaloneasfirstlinetherapyforpatientswithunfavorablecancerofunknownprimaryamulticenterretrospectivecohortstudy AT zhousanzheng pd1pdl1inhibitorspluschemotherapyversuschemotherapyaloneasfirstlinetherapyforpatientswithunfavorablecancerofunknownprimaryamulticenterretrospectivecohortstudy AT tinghuagao pd1pdl1inhibitorspluschemotherapyversuschemotherapyaloneasfirstlinetherapyforpatientswithunfavorablecancerofunknownprimaryamulticenterretrospectivecohortstudy AT meitingchen pd1pdl1inhibitorspluschemotherapyversuschemotherapyaloneasfirstlinetherapyforpatientswithunfavorablecancerofunknownprimaryamulticenterretrospectivecohortstudy AT anqihu pd1pdl1inhibitorspluschemotherapyversuschemotherapyaloneasfirstlinetherapyforpatientswithunfavorablecancerofunknownprimaryamulticenterretrospectivecohortstudy AT yunjiehuang pd1pdl1inhibitorspluschemotherapyversuschemotherapyaloneasfirstlinetherapyforpatientswithunfavorablecancerofunknownprimaryamulticenterretrospectivecohortstudy AT qiufanzheng pd1pdl1inhibitorspluschemotherapyversuschemotherapyaloneasfirstlinetherapyforpatientswithunfavorablecancerofunknownprimaryamulticenterretrospectivecohortstudy AT xinan pd1pdl1inhibitorspluschemotherapyversuschemotherapyaloneasfirstlinetherapyforpatientswithunfavorablecancerofunknownprimaryamulticenterretrospectivecohortstudy AT congxue pd1pdl1inhibitorspluschemotherapyversuschemotherapyaloneasfirstlinetherapyforpatientswithunfavorablecancerofunknownprimaryamulticenterretrospectivecohortstudy AT yuchencai pd1pdl1inhibitorspluschemotherapyversuschemotherapyaloneasfirstlinetherapyforpatientswithunfavorablecancerofunknownprimaryamulticenterretrospectivecohortstudy AT yanxiashi pd1pdl1inhibitorspluschemotherapyversuschemotherapyaloneasfirstlinetherapyforpatientswithunfavorablecancerofunknownprimaryamulticenterretrospectivecohortstudy |